Table 2. GFAP+, SVN+ and SVN+/GFAP+ exosomes measured by imaging flow cytometry as a percentage of all CD9+ events.

	GFAP+ (% Total CD9+ Exosomes)					Survivin+ (% Total CD9+ Exosomes)					Survivin+/GFAP+ (% Total CD9+ Exosomes)
Patient	Baseline	8 Weeks	% change	Extended	% change	Baseline	8 Weeks	% change	Extended	% change	Baseline	8 Weeks	% change	Extended	% change
1	23.7	25.9	9%	33.1	40%	12.1	0.4	−97%	0.9	−93%	10.4	0.3	−98%	0.6	−94%
2	18.2	16.9	−7%	26.3	45%	35.0	17.1	−51%	11.4	−67%	27.2	11.5	−58%	9.0	−67%
3	22.9	20.5	−10%	18.7	−18%	0.8	1.2	53%	0.3	−63%	0.6	0.4	−31%	0.2	−65%
4	25.0	30.3	21%			5.1	2.0	−61%			3.2	1.2	−63%
5	19.8	19.4	−2%			1.6	14.1	781%			0.6	9.7	1417%
6	24.9	19.1	−23%			6.7	31.7	373%			4.4	21.6	393%
7	21.0	17.8	−15%	16.0	−24%	6.3	27.5	340%	46.5	644%	4.4	19.8	349%	37.6	753%
8	27.1	26.5	−2%			5.3	2.3	−57%			3.8	1.4	−63%
C1	2.9					0.1					0.0
C2	3.2					0.0					0.0
C3	2.7					1.2					0.1

Glioma patients 1-3 and 4-8 and non-cancer healthy controls (C1, C2 and C3) are shown. Glioma patient #4 is not shown due to failure to complete the prime-boost vaccine regimen due to rapid tumor progression. Baseline measurements were made on serum obtained prior to first vaccination and 8-week values were obtained 2 weeks after administration of the last of 4 vaccine doses.